Generating and Expanding Conventional Type 1 Dendritic Cells
- 1Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute National Institutes of Health Bethesda Maryland USA
Abstract
Conventional type 1 dendritic cells (cDC1s) are specialized antigen‐presenting cells that play essential roles in cross‐presentation, immunity to intracellular pathogens, and antitumor immune responses. Their low abundance and limited accessibility in blood and many tissues have driven extensive efforts to generate and expand cDC1s for mechanistic and translational studies. Over the past two decades, advances in cDC1 biology have transformed the field from heterogeneous bone marrow‐derived cultures to increasingly sophisticated platforms that generate, enrich, or expand bona fide cDC1s, alongside approaches whose products remain best described as cDC1‐like. Here, we review cytokine‐driven cultures, Notch ligand‐supported systems, human CD34+ progenitor and induced pluripotent stem cell‐derived platforms, transcription factor‐based programming, and endogenous cDC1 expansion. We distinguish bona fide cDC1s, cDC1‐enriched cultures, and cDC1‐like cells and compare these approaches by lineage validation, enrichment, yield, culture duration, function, scalability, and translational maturity. Together, these platforms provide complementary tools for cDC1 research and therapeutic development.
Related
- 1115 Cross-priming by type-1 conventional dendritic cells is critically involved in the efficacy of radiotherapy against cancer
- Activation of conventional and plasmacytoid dendritic cells and enhancement of anti-viral immune responses by Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 and Streptococcus thermophilus OLS3059
- Dysbiosis-induced expansion of AXL-positive inflammatory type 3 dendritic cells triggers preclinical autoimmunity
- Dendritic hotspots support switching between competing rules without expanding the cortical engram
- Unexpected detrimental role of plasmacytoid dendritic cells during viral infections of the lungs
BibTeX
@article{sharma2026generating,
title = {{Generating and Expanding Conventional Type 1 Dendritic Cells}},
author = {Sukriti Sharma and Shandré Pillay and Christian T. Mayer},
journal = {European Journal of Immunology},
year = {2026},
month = oct,
doi = {10.1002/eji.70307},
url = {https://doi.org/10.1002/eji.70307},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Generating and Expanding Conventional Type 1 Dendritic Cells
AU - Sukriti Sharma
AU - Shandré Pillay
AU - Christian T. Mayer
PY - 2026
DA - 2026/10/28
JO - European Journal of Immunology
DO - 10.1002/eji.70307
UR - https://doi.org/10.1002/eji.70307
AB - Conventional type 1 dendritic cells (cDC1s) are specialized antigen‐presenting cells that play essential roles in cross‐presentation, immunity to intracellular pathogens, and antitumor immune responses. Their low abundance and limited accessibility in blood and many tissues have driven extensive efforts to generate and expand cDC1s for mechanistic and translational studies. Over the past two decades, advances in cDC1 biology have transformed the field from heterogeneous bone marrow‐derived cultures to increasingly sophisticated platforms that generate, enrich, or expand bona fide cDC1s, alongside approaches whose products remain best described as cDC1‐like. Here, we review cytokine‐driven cultures, Notch ligand‐supported systems, human CD34+ progenitor and induced pluripotent stem cell‐derived platforms, transcription factor‐based programming, and endogenous cDC1 expansion. We distinguish bona fide cDC1s, cDC1‐enriched cultures, and cDC1‐like cells and compare these approaches by lineage validation, enrichment, yield, culture duration, function, scalability, and translational maturity. Together, these platforms provide complementary tools for cDC1 research and therapeutic development.
SN - 0014-2980
SN - 1521-4141
ER -